PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers.

Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease missed by conventional imaging, investigators report.

Nearly half of high-risk prostate cancer patients classified as nonmetastatic by traditional imaging show metastases when ...

Researchers at UCLA have unveiled startling findings using PSMA-PET imaging that reveal nearly half of patients diagnosed ...

This advanced imaging technology plays a critical role in redefining how prostate cancer is staged. PSMA-PET imaging uses tiny amounts of radioactive “tracers,” called radiotracers, that binds to ...

PSMA PET CT showed a solitary pelvic node with no prostate fossa recurrence. The patient underwent salvage radiotherapy including both fossa and pelvic node fields. PSA continued to rise ...

Advanced imaging reveals hidden metastases in high-risk prostate cancer cases, offering new insights for better diagnosis and treatment strategies.

PSMA-PET imaging has higher sensitivity than conventional imaging and can detect radiorecurrent prostate cancer at lower PSA levels. PSMA-PET imaging can detect radiorecurrent prostate cancer ...

Lantheus (LNTH) is a strong buy with a dominant market position in radiopharmaceuticals and promising growth in Alzheimer's ...

Jacob E. Berchuck, MD, discusses how a new epigenomic platform may influence the accessibility of PSMA-based therapies, ...